Download PDF
Semin Thromb Hemost 2003; 29(1): 055-060
DOI: 10.1055/s-2003-37939
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Orthopedic Outcome Studies and Cost Issues

Louis M. Aledort
  • Professor of Medicine, Mount Sinai School of Medicine, New York, New York
Further Information

Publication History

Publication Date:
17 March 2003 (online)

    Permissions and Reprints

ABSTRACT

Standard therapy for years was on-demand therapy. Readers will learn of results of clinical experience in many different countries with a prophylactic approach to therapy as well as ongoing experimental designs to define optimal therapy. The costs of current prophylaxis regimens will be discussed.

KEYWORD

Hemophilia - prophylaxis - factor concentrates - orthopedic outcomes - cost

REFERENCES

  • 1 Ahlberg Å. Haemophilia in Sweden. VII: Incidence, treatment and prophylaxis of arthropathy and other musculoskeletal manifestations of haemophilia A and B.  Acta Orthop Scand . 1965;  77(Suppl) 7-80
    PubMedGoogle Scholar
  • 2 Aronstam A, Rainsfad S G, Painter M J. Patterns of bleeding in adolescents with severe hemophilia A.  BMJ . 1979;  1 469-470
    PubMedGoogle Scholar
  • 3 Allain J P. Dose requirement for replacement therapy in hemophilia A.  Thromb Haemost . 1975;  42 825-831
    PubMedGoogle Scholar
  • 4 Brackmann H H, Eickhoff H J, Oldenburg J, Seuser A, Hammerstein U. Controlled study of long-term treatment in children and adolescents at the hemophilia center, Bonn. In: Prophylactic Treatment of Hemophilia A and B: Current and Future Perspectives New York: Science and Medicine 1994: 9-12
    Google Scholar
  • 5 Schramm W. Consensus recommendations for hemophilia treatment in Germany. In: Prophylactic Treatment of Hemophilia A and B: Current and Future Perspectives New York: Science and Medicine 1994: 13-14
    Google Scholar
  • 6 Rosendaal F R. An overview of 20 years of hemophilia treatment in the Netherlands. In: Prophylactic Treatment of Hemophilia A and B: Current and Future Perspectives New York: Science and Medicine 1994: 18-20
    Google Scholar
  • 7 Savidge G F, Majumdar G, Spence K. Experience from St Thomas' Hospital, London. In: Prophylactic Treatment of Hemophilia A and B: Current and Future Perspectives New York: Science and Medicine 1994: 15-17
    Google Scholar
  • 8 Nilsson I M, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.  J Intern Med . 1992;  232 25-32
    CrossrefPubMedGoogle Scholar
  • 9 Kreuz W, Escuriola-Ettinghausen C, Funk M, Schmidt H, Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start?-The German experience.  Haemophilia . 1998;  4 413-417
    CrossrefPubMedGoogle Scholar
  • 10 Pettersson H, Gilbert M. Musculoskeletal and other haemorrhagic complications. In: Diagnostic Imaging in Hemophilia Berlin: Springer-Verlag 1985: 55-60
    Google Scholar
  • 11 Aledort L M, Haschmeyer R H, Pettersson H, and The Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs.  J Intern Med . 1994;  236 391-399
    CrossrefPubMedGoogle Scholar
  • 12 Ljung R CR. Prophylactic treatment in Sweden-overtreatment or optimal model?.  Haemophilia . 1998;  4 409-412
    CrossrefPubMedGoogle Scholar
  • 13 Bohn R L, Avorn J, Glynn R J. et al . Prophylactic use of factor VIII: an economic evaluation.  Thromb Haemost . 1998;  79 932-937
    PubMedGoogle Scholar
  • 14 Björkman S, Carlsson M, Berntorp E, Stenberg P. Pharmacokinetics of factor VIII in humans.  Clin Pharmacokinetics . 1992;  22 385-395
    PubMedGoogle Scholar
      >